Prostate cancer incidence rates are lower among men of Asian descent than among white men. It has not been determined whether these lower rates are the result of less prostate cancer screening or other factors. This study focuses on the association of Asian race/ethnicity and the rates of prostate cancer diagnosis in the Reduction by Dutasteride of Cancer Events (REDUCE) study. REDUCE was a 4-year, multicenter, randomized trial of dutasteride versus placebo for prostate cancer prevention.
Men eligible for this study ranged from 50 to 75 years old, had a PSA result between 2.5 and 10 ng/ml, and a negative prostate biopsy before the study began. The participants underwent PSA-independent biopsies at 2 and 4 years.
Logistic regression was used to analyze the association between Asian race/ethnicity, Caucasian race/ethnicity, and prostate cancer diagnosis. After adjusting for potential confounders, the study found that participants of Asian descent were significantly less likely to be diagnosed with prostate cancer.
This study suggests that prostate cancer rates are lower among men of Asian race/ethnicity, but the reason why is not yet clear. Whether there are genetic or lifestyle factors involved has yet to be determined .
Source: Vidal, A. C., Oyekunle, T., Feng, T., Freedland, A. R., Moreira, D., Castro-Santamaria, R., Andriole, G. L., Freedland, S. J., & Allott, E. H. (2020). Asian Race and Risk of Prostate Cancer: Results from the REDUCE Study. Cancer Epidemiology Biomarkers & Prevention, 29(11), 2165–2170. https://doi.org/10.1158/1055-9965.epi-20-0646